Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Absci Corp

ABSI ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$9.18

▼ -2.96%

Market Cap $1.58B · Vol 682.73K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.58B

Small Cap

Div Yield

N/A

EPS Growth

+4.32%

YoY

RSI (14)

70.56

Momentum

Beta

2.44

vs Market

52W High

$12.06

23.85% below

52W Low

$2.25

308.91% above

Volume

682.73K

Avg 1.12M

P/B

2.79

Price-to-book

ROE

-62.50%

Return on equity

Free Float

88.03%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Absci Corp (ABSI) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ABSI pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+2.80%

-10.26%

+65.70%

+260.00%

YTD

+163.04%

+206.00%

+459.76%

-63.29%

Financials & Valuation

TTM · Annual

Total Revenue	$2.80M
Net Income	$-115,183,000.00
Revenue Growth (YoY)	-46.37%
Gross Margin	100.00%
Operating Margin	-4,479.21%
Net Profit Margin	-4,113.68%
ROE	-62.50%
ROA · ROIC	-53.55% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	170.48
P/B	2.79
P/FCF	N/A
EPS Growth	+4.32%
Outstanding Shares	171.61M

Technical Indicators

50-Day SMA	$8.74
200-Day SMA	$4.86
RSI (14)	70.56
Beta	2.44
52-Week High	$12.06
52-Week Low	$2.25

Volume Today	682.73K
Avg Daily Volume (30D)	1.12M
Relative Volume	0.61x
Volatility (10D)	51.69
Volatility (30D)	78.04
Free Float	88.03%

Analyst Consensus

BUY

Current Price $9.18

Mean Target $13.88

52W Low$2.25 52W High$12.06

Current

Target

$2.25 $12.06

Current Analyst target

+51.14% upside potential · 10 analysts

Identifiers

ExchangeNasdaq

FIGIBBG011N54DC3

ISINUS00091E1091

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.